BiotechTube

ONO-7684 + ONO-7684 Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Thromboembolism

Conditions

Venous Thromboembolism

Trial Timeline

Jan 17, 2019 → Aug 23, 2019

NCT ID
NCT03919890

About ONO-7684 + ONO-7684 Placebo

ONO-7684 + ONO-7684 Placebo is a phase 1 stage product being developed by Ono Pharmaceutical for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT03919890. Target conditions include Venous Thromboembolism.

What happened to similar drugs?

6 of 20 similar drugs in Venous Thromboembolism were approved

Approved (6) Terminated (2) Active (13)
✅Dalteparin (Fragmin) + Unfractionated heparinPfizerApproved
✅Apixaban + Standard of CarePfizerApproved
✅ApixabanBristol Myers SquibbApproved
✅enoxaparin sodiumSanofiApproved
✅enoxaparinSanofiApproved
✅Long DOAC + Short DOACBayerApproved
🔄Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03919890Phase 1Completed

Competing Products

20 competing products in Venous Thromboembolism

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
35
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Standard of CareDaiichi SankyoPhase 3
40
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
35
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
40
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
40
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2/3
38
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
26
dalteparin injectionEisaiPhase 3
32
Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K AntagonistJohnson & JohnsonPhase 2
35